344,880 Shares in Allogene Therapeutics, Inc. $ALLO Purchased by Kingstone Capital Partners Texas LLC

Key Points

• Kingstone Capital Partners Texas LLC has made a new investment of $390,000 in Allogene Therapeutics, acquiring 344,880 shares during the second quarter, resulting in an ownership of 0.16% of the company.
• Notable institutional investors, including Bank of America Corp DE and Ameriprise Financial Inc., have also significantly increased their stakes in Allogene Therapeutics during the fourth quarter, reflecting growing interest in the firm's stock.
• Following recent earnings reports, Allogene Therapeutics has received mixed analyst ratings, with a consensus average rating of "Moderate Buy" and a price target of $8.44, despite a recent downgrade to "sell" by Wall Street Zen.

Kingstone Capital Partners Texas LLC bought a new stake in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 344,880 shares of the company's stock, valued at approximately $390,000. Kingstone Capital Partners Texas LLC owned approximately 0.16% of Allogene Therapeutics at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Goldman Sachs Group Inc. grew its position in shares of Allogene Therapeutics by 177.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 5,853,974 shares of the company's stock worth $8,547,000 after buying an additional 3,747,397 shares during the last quarter. Frazier Life Sciences Management L.P. lifted its stake in Allogene Therapeutics by 34.9% during the first quarter. Frazier Life Sciences Management L.P. now owns 3,868,750 shares of the company's stock worth $5,648,000 after purchasing an additional 1,001,000 shares in the last quarter. Two Sigma Advisers LP increased its holdings in Allogene Therapeutics by 12.1% in the fourth quarter. Two Sigma Advisers LP now owns 2,702,200 shares of the company's stock valued at $5,756,000 after buying an additional 291,800 shares during the last quarter. DAFNA Capital Management LLC raised its position in Allogene Therapeutics by 11.3% in the 1st quarter. DAFNA Capital Management LLC now owns 1,380,118 shares of the company's stock valued at $2,015,000 after purchasing an additional 140,000 shares during the last quarter. Finally, Northern Trust Corp lifted its holdings in Allogene Therapeutics by 4.5% in the fourth quarter. Northern Trust Corp now owns 1,305,232 shares of the company's stock valued at $2,780,000 after acquiring an additional 56,693 shares during the period. Institutional investors own 83.63% of the company's stock.

Allogene Therapeutics Price Performance

Shares of NASDAQ:ALLO traded up $0.01 during trading on Monday, hitting $1.17. 2,589,687 shares of the company's stock were exchanged, compared to its average volume of 2,890,283. Allogene Therapeutics, Inc. has a 52-week low of $0.86 and a 52-week high of $3.78. The business's 50-day simple moving average is $1.18 and its 200 day simple moving average is $1.32. The company has a market cap of $259.60 million, a price-to-earnings ratio of -1.05 and a beta of 0.36.

Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) last released its earnings results on Wednesday, August 13th. The company reported ($0.23) EPS for the quarter, topping analysts' consensus estimates of ($0.28) by $0.05. On average, sell-side analysts anticipate that Allogene Therapeutics, Inc. will post -1.28 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on ALLO shares. Wall Street Zen downgraded shares of Allogene Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, September 13th. JPMorgan Chase & Co. reissued a "neutral" rating on shares of Allogene Therapeutics in a report on Monday, August 4th. Finally, JMP Securities reissued a "market perform" rating on shares of Allogene Therapeutics in a research note on Monday, August 4th. Nine research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $8.44.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).